JP2023552827A5 - - Google Patents
Info
- Publication number
- JP2023552827A5 JP2023552827A5 JP2023534948A JP2023534948A JP2023552827A5 JP 2023552827 A5 JP2023552827 A5 JP 2023552827A5 JP 2023534948 A JP2023534948 A JP 2023534948A JP 2023534948 A JP2023534948 A JP 2023534948A JP 2023552827 A5 JP2023552827 A5 JP 2023552827A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- sulfur
- oxygen
- independently selected
- heteroatoms independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123330P | 2020-12-09 | 2020-12-09 | |
| US63/123,330 | 2020-12-09 | ||
| PCT/US2021/062640 WO2022125790A1 (en) | 2020-12-09 | 2021-12-09 | Irak degraders and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552827A JP2023552827A (ja) | 2023-12-19 |
| JP2023552827A5 true JP2023552827A5 (enExample) | 2024-12-17 |
| JP7832945B2 JP7832945B2 (ja) | 2026-03-18 |
Family
ID=81973811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534948A Active JP7832945B2 (ja) | 2020-12-09 | 2021-12-09 | Ｉｒａｋ分解剤およびそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230096599A1 (enExample) |
| EP (1) | EP4259128A4 (enExample) |
| JP (1) | JP7832945B2 (enExample) |
| KR (1) | KR20230130179A (enExample) |
| CN (1) | CN116669722A (enExample) |
| AR (1) | AR124294A1 (enExample) |
| AU (1) | AU2021396308A1 (enExample) |
| CA (1) | CA3200608A1 (enExample) |
| CO (1) | CO2023006818A2 (enExample) |
| IL (1) | IL303458A (enExample) |
| MX (1) | MX2023006719A (enExample) |
| TW (1) | TW202237601A (enExample) |
| WO (1) | WO2022125790A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN116867758A (zh) * | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| WO2024020084A1 (en) * | 2022-07-20 | 2024-01-25 | Bristol-Myers Squibb Company | Heteroaryl compounds as ligand directed degraders of irak4 |
| IL325910A (en) * | 2023-07-13 | 2026-03-01 | Increland | Aromatic compound, pharmaceutical preparation comprising the same, and use thereof |
| CN121816348A (zh) | 2023-08-11 | 2026-04-07 | 深圳众格生物科技有限公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
| WO2025051160A1 (zh) * | 2023-09-08 | 2025-03-13 | 北京华益健康药物研究中心 | 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途 |
| CN120025333A (zh) * | 2023-11-22 | 2025-05-23 | 广东东阳光药业股份有限公司 | 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途 |
| WO2025168131A1 (zh) * | 2024-02-08 | 2025-08-14 | 清华大学 | 一种多靶降解剂及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6126131B2 (ja) * | 2012-01-10 | 2017-05-10 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| CA2988461A1 (en) * | 2015-06-26 | 2016-12-29 | Dana-Farber Cancer Institute, Inc. | Fused bicyclic pyrimidine derivatives and uses thereof |
| WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3445765A4 (en) * | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| EP3710443A1 (en) * | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020010227A1 (en) * | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CA3119773A1 (en) * | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021053555A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Glue degraders and methods of use thereof |
| KR20230005160A (ko) * | 2020-03-19 | 2023-01-09 | 카이메라 쎄라퓨틱스 인코포레이티드 | Mdm2 분해제 및 이의 용도 |
-
2021
- 2021-12-09 IL IL303458A patent/IL303458A/en unknown
- 2021-12-09 AU AU2021396308A patent/AU2021396308A1/en not_active Abandoned
- 2021-12-09 KR KR1020237023081A patent/KR20230130179A/ko active Pending
- 2021-12-09 CN CN202180090865.XA patent/CN116669722A/zh active Pending
- 2021-12-09 EP EP21904406.2A patent/EP4259128A4/en active Pending
- 2021-12-09 US US17/643,560 patent/US20230096599A1/en not_active Abandoned
- 2021-12-09 JP JP2023534948A patent/JP7832945B2/ja active Active
- 2021-12-09 CA CA3200608A patent/CA3200608A1/en active Pending
- 2021-12-09 WO PCT/US2021/062640 patent/WO2022125790A1/en not_active Ceased
- 2021-12-09 AR ARP210103419A patent/AR124294A1/es unknown
- 2021-12-09 TW TW110146161A patent/TW202237601A/zh unknown
- 2021-12-09 MX MX2023006719A patent/MX2023006719A/es unknown
-
2023
- 2023-05-25 CO CONC2023/0006818A patent/CO2023006818A2/es unknown
-
2025
- 2025-02-18 US US19/056,013 patent/US20250375526A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552827A5 (enExample) | ||
| IL315310A (en) | Irak degraders and uses thereof | |
| Jung et al. | Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer | |
| JP2022527114A5 (enExample) | ||
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR124294A1 (es) | Degradadores de irak y sus usos | |
| ES3002745T3 (en) | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same | |
| JP2014503504A (ja) | ミトコンドリアの電子伝達系の複合体ｉｉｉの活性の阻害剤、及び疾患を治療するためのその使用 | |
| JP2013506715A5 (enExample) | ||
| TW200813055A (en) | Spiro-conjugated cyclic group containing compound and use thereof | |
| JP2013529196A5 (enExample) | ||
| RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| ATE336991T1 (de) | Bis(thio-hydrazid amid) verbindungen zur behandlung von mehrfach resistenten krebs | |
| JP2015531760A5 (enExample) | ||
| JP2022176252A (ja) | キレート化されたｐｓｍａ阻害剤 | |
| JP2018513875A5 (enExample) | ||
| RU2017132330A (ru) | Соли производного хиназолина и способ их получения | |
| ES3003782T3 (en) | Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group | |
| JP2024528986A5 (enExample) | ||
| JP2010510216A5 (enExample) | ||
| JP2018538244A5 (enExample) | ||
| JP2021521169A (ja) | リン脂質−フラバグリン複合体およびそれを標的癌治療に使用する方法 | |
| JP5555494B2 (ja) | 癌を治療するためのアミノ化ヒドロキシキノリン類誘導体 | |
| FI68826B (fi) | Foerfarande foer framstaellning av 6,7,8,9-tetrahydro-4h-pyrido(1,2-a)pyrimidin-4-on-derivat | |
| US20200140406A1 (en) | Trioxolane agents |